Author

Q. Zhang

Observed institution: Seagen (United States)

OpenAlex ID: A5074290076

INTERIM RESULTS FROM a PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA

2017 · A.F. Herrera, A.J. Moskowitz, et al. · Hematological Oncology · 26

833O A phase Ib study result of HMPL-689, a PI3Kδ inhibitor, in Chinese patients with relapsed/refractory lymphoma

2021 · J. Cao, Z. Li, et al. · Annals of Oncology · 3

Works count: 2

Citation count: 29

H-index: 2

I10-index: 1